SanBio’s SB623 meets in Phase II for TBI

SanBio Co. Ltd. (Tokyo:4592) reported Nov. 1 that intracranial SB623 cells met the primary endpoint of improving motor function as measured by the change from baseline in Fugl-Meyer Motor Scale (FMMS) score at 24 weeks vs. placebo in the Phase II STEMTRA trial to treat patients with chronic motor deficits due to traumatic brain injury (TBI) (8.7 vs. 2.4 points). The company plans to submit an NDA in Japan for SB623 during its fiscal year ending January 2020...